Tuesday, July 17, 2018
Human papilloma virus (HPV) vaccines are designed to prevent infection by certain types of human papilloma virus. The currently available vaccines generally protect against two, four, or nine types of HPV infection. But all vaccines protect against at least...
The findings from a study published in CANCER, a peer-reviewed journal of the American Cancer Society, shows that pediatric neuroblastoma patients are at elevated risk for long-term psychological impairment. In addition, those who experience such impairment as they get older...
In a randomized phase III trial patients with surgically removed pancreatic cancer who received modified FOLFIRINOX (mFOLFIRINOX), a chemotherapy regimen containing four different medicines including oxaliplatin, leucovorin, and irinotecan administered intravenously (IV) at day 1, followed by 5-fluorouracil via...
A randomized, phase III trial, called PREOPANC-1, funded in part by the Dutch Cancer Society KWF/Koningin Wilhelmina Fonds, found that people who received chemotherapy with radiation, also known as chemoradiotherapy, before pancreatic cancer surgery had better disease-free survival than...
New evidence published today in the Cochrane Library shows that human papilloma virus (HPV) vaccines protect against cervical lesions in young women, particularly in those who are vaccinated between the ages of 15 and 26. The review also summarizes...
“When I was diagnosed with breast cancer in 2003, I was ready to fight for my life, but I didn’t know about mouth sores or how hard they would make it for me.” Alex F. developed white, pus-filled sores only...
Deep vein thrombosis (DVT) and pulmonary embolism (PE), collectively known as venous thromboembolism (VTE), occurs frequently in patients with cancer and contributes to elevated morbidity and mortality. In cancer patients VTE is an important and increasingly frequent clinical challenge. Roughly...
Cancer-related fatigue is not the same as being tired from the activities of daily life. In most cases, everyday, 'normal' fatigue - especially and the end of a busy day - doesn’t last long. It often gets better with...
AbbVie and Rice University have entered into a joint research collaboration to establish the K.C. Nicolaou Research Accelerator. According to both AbbVie and Rice University, the research at the Accelerator will focus on synthesizing novel cytotoxic agents for use in...
Among patients with newly diagnosed advanced non-small cell lung cancer (NSCLC) with high tumor mutational burden (TMB, >10 mutations/Mb) who received nivolumab (Opdivo™; Bristol-Myers Squibb Company ) plus ipilimumab (Yervoy®; Bristol-Myers Squibb Company) had significantly improved progression-free survival (PFS)...

Related articles